What is claimed is:

1. Use of ~~A~~a ~~method of~~pharmaceutical composition in the manufacture of a medicament for treating chemotherapy-induced diarrhea (CID) in a human subject undergoing chemotherapy ~~comprising administering to a subject~~and in need thereof, the ~~a~~ composition comprising an effective amount of crofelemer to treat CID.

2. The use~~method~~ of claim 1, wherein the crofelemer ~~may be~~ is to be administered in combination with ~~other~~ the chemotherapy ~~agents~~.

3. The use~~method~~ of claim 1, wherein the crofelemer is to be administered at the same time as the chemotherapy to reduce or delay the onset of CID.

4. The use ~~method~~ of claim 1, wherein the crofelemer is to be administered before chemotherapy ~~to prevent, reduce or delay the onset of CID~~.

5. The use ~~method~~ of claim 1, wherein the crofelemer is to be administered after chemotherapy ~~to reduce the onset of or treat CID~~.

6. The use ~~method~~ of any previous claim, wherein the chemotherapy is selected from alkylating agents, anthracyclines, cytoskeletal disruptors (taxanes), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based agents and retinoids.

7. The use ~~method~~ of claim 6, wherein the chemotherapy comprises one or more tyrosine kinase inhibitors.

8. The use ~~method~~ of claim 7, wherein the tyrosine kinase inhibitor is selected from lapatinib, sunitinib, sorafenib, erlotinib, gefitinib, axitinib, imatinib, nilotinib, dasatinib, cabozantinib, ruxolitinib, neratinib, bosutinib, pazopanib, afatninib, lenvatinib, tucatinib, vandetanib, ceritinib, crizotinib, dacomitinib, and valatinib.

9. The use ~~method~~ of claim 7, wherein the tyrosine kinase inhibitor (TKI) is selected from anaplastic lymphoma kinase (ALK) TKI (e.g., crizotinib, ceritinib and alectinib)~~;~~.

10. The use ~~method~~ of claim 6, wherein the chemotherapy is a phosphoinositide 3-kinase inhibitor.

11. The use ~~method~~ of claim 10, wherein the phosphoinositide 3-kinase inhibitor is alpelisib.

12. The use ~~method~~ of claim 6, wherein the chemotherapy is a CDK (cyclin-dependent kinase) 4/6/ inhibitor, optionally, abemaciclib.

13. The use ~~method~~ of any one of claims 1 to 6, wherein the chemotherapy comprises one or more HER (Human epidermal growth factor receptor) inhibitors.

14. The use ~~method~~ of claim 9, wherein the HER (Human epidermal growth factor receptor) inhibitor is selected from RG7116, RG1273 (pertuzumab, Perjeta®), RG3502 (trastuzumab emantasine, T-DMI), RG597 (trastuzumab, HERCEPTIN), RGA201 (RG7160), erlotinib (Tarceva®), dacomitinib (PF-00299804), PF-05280014 (Pfizer's biosimilar mAB to RG597).

~~15. The method of claim 1, wherein the crofelemer is administered after a subject begins to exhibit symptoms of CID.~~

~~16.~~15. The use ~~method~~ of claim 1, wherein the crofelemer is to be administered for the duration of treatment with the chemotherapy.

~~17. The method of claim 1, wherein the crofelemer is administered until symptoms of CID are ameliorated and then crofelemer is discontinued.~~

~~18.~~16. The use ~~method~~ of claim 1, wherein the ~~administering comprises administering~~ composition comprises an amount suitable for administration of ~~about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about~~ 250 mg two times per day~~;~~ or ~~administering~~ administration of about 500 mg two times per day ~~of crofelemer to a subject in need thereof~~.

~~19.~~17. The use ~~method~~ of claim 1, wherein the crofelemer is to be administered as an enteric coated oral dosage form.

~~20. The method of claim 1, wherein the crofelemer is administered as an oral dosage form that is not enteric coated.~~

~~21.~~18. The use ~~method~~ of claim 1, wherein the subject can tolerate ~~a~~ the chemotherap~~eutic agent~~y that the subject could not tolerate without the administration of crofelemer or can tolerate a higher

dosage of ~~chemotherapeutic~~ chemotherapy than the subject could tolerate without administration of crofelemer.

~~22.~~19. The use ~~method~~ of claim 1, wherein a subject is considered treated if the subject demonstrates one or more of a decrease in the number of bowel movements per day, a decrease in the number of watery bowel movements per day, an improvement in the daily abdominal score for pain or discomfort, an improvement in the score for daily stool consistency, a decrease in stool consistency, a decrease in the number of days per week that subjects experienced urgency, a decrease in the number of days per week that subjects experienced fecal incontinence, or a decrease in the unscheduled visit for a significant worsening of diarrhea.

~~23.~~20. The use ~~method~~ of claim 1, wherein the administration results in a decrease in 1, 2 or 3 Grades of the Grade of diarrhea according to the Common Toxicity Criteria.

~~24.~~21. The use ~~method~~ of claim 1, wherein the subject is undergoing chemotherapy to treat a cancer selected from breast cancer, ovarian cancer, prostate cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, thyroid cancer, oral or oropharyngeal cancer, astrocytoma, sarcoma, mesothelioma, meningioma, lymphoma, myeloma, head and neck cancer, lung cancer, carcinoma (e.g., squamous cell carcinoma), malignant melanoma, peritoneal cancer, gastric cancer, hepatic cancer, colorectal cancer, gallbladder cancer, bone cancer, pancreatic cancer, tongue cancer, esophageal cancer, brain tumor, brain stem glioma, a metastases thereof, and leukemia.

~~25~~22. Use of ~~A~~a composition ~~method of~~ in the manufacture of a medicament for treating CID in a human subject undergoing chemotherapy for HER positive breast cancer, ~~said method comprising administering to said human subject a~~wherein the composition ~~comprising~~ comprises ~~an~~ crofelemer at a dose of 125 mg twice per day, wherein the chemotherapy is trastuzumab, pertuzumab, docetaxel, paclitaxel, or neratinib, or a combination thereof, with or without carboplatin.